{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:02:40Z","timestamp":1792047760939,"version":"4.4.0"},"reference-count":247,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016156","name":"US Army Medical Research and Development Command","doi-asserted-by":"publisher","award":["W81XWH-18-1-0064"],"award-info":[{"award-number":["W81XWH-18-1-0064"]}],"id":[{"id":"10.13039\/100016156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016156","name":"US Army Medical Research and Development Command","doi-asserted-by":"publisher","award":["HT9425-24-1-0084"],"award-info":[{"award-number":["HT9425-24-1-0084"]}],"id":[{"id":"10.13039\/100016156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer remains the most commonly diagnosed malignancy among women worldwide. While breast cancer treatment outcomes have improved in recent years, there remains an unmet medical need for therapeutics that can be used with curative intent in the most aggressive breast cancer subtypes and for those cancers that have metastasized. In recent years, the success of T-cell-based therapies and other technologies that boost antitumor activities of immune cells have increased interest in using natural killer (NK) cell-based immunotherapies to treat solid tumors. These innate lymphoid cells can identify and eliminate tumor cells through their intrinsic cytotoxic activities and their ability to modulate the immune response through cytokine production. Owing to their lack of T-cell receptors, NK cells can also be used in the allogeneic setting, and strategies to develop and establish NK cells as therapeutics in breast cancer are currently being explored. In this review, we describe NK cell biology as it relates to breast cancer pathobiology and treatment outcomes and discuss how NK cell biology can be exploited and manipulated in the development of new therapeutics for breast cancer. Additionally, we review the role of estrogens in regulating NK cell activity and discuss how endocrine therapies targeting the estrogen receptor signaling axis could be employed as an approach to increase tumor immunity and the efficacy of NK-cell-directed immunotherapies.<\/jats:p>","DOI":"10.1210\/endrev\/bnaf014","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:22:54Z","timestamp":1746778974000},"page":"690-708","source":"Crossref","is-referenced-by-count":9,"title":["The Roles of Natural Killer Cells in Breast Cancer Pathobiology and Their Regulation by Estrogens"],"prefix":"10.1210","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8028-9603","authenticated-orcid":false,"given":"Jovita","family":"Byemerwa","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Cancer Biology, Duke University School of Medicine , Durham, NC 27710 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yi","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology, Duke University School of Medicine , Durham, NC 27710 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-4700","authenticated-orcid":false,"given":"Donald P","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology, Duke University School of Medicine , Durham, NC 27710 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"1","key":"2025091917041560500_bnaf014-B1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2025091917041560500_bnaf014-B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2025091917041560500_bnaf014-B3","doi-asserted-by":"crossref","first-page":"18301","DOI":"10.1038\/s41598-023-45438-z","article-title":"Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning","volume":"13","author":"Zhong","year":"2023","journal-title":"Sci Rep"},{"issue":"10125","key":"2025091917041560500_bnaf014-B4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"2025091917041560500_bnaf014-B5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"1","key":"2025091917041560500_bnaf014-B6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"issue":"3","key":"2025091917041560500_bnaf014-B7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"2025091917041560500_bnaf014-B8","first-page":"216","article-title":"CDK4\/6 inhibitors: game changers in the management of hormone receptor\u2013positive advanced breast cancer?","volume":"32","author":"Shah","year":"2018","journal-title":"Oncology (Williston Park)"},{"issue":"10087","key":"2025091917041560500_bnaf014-B9","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"2025091917041560500_bnaf014-B10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025091917041560500_bnaf014-B11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clbc.2011.03.018","article-title":"Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer","volume":"11","author":"Burris","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"19","key":"2025091917041560500_bnaf014-B12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2025091917041560500_bnaf014-B13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/fon.13.7","article-title":"Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer","volume":"9","author":"Peddi","year":"2013","journal-title":"Future Oncol"},{"issue":"10371","key":"2025091917041560500_bnaf014-B14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"10390","key":"2025091917041560500_bnaf014-B15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"2025091917041560500_bnaf014-B16","article-title":"Correction: society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2025091917041560500_bnaf014-B17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PPO.0000000000000497","article-title":"Immunotherapy in triple-negative breast cancer","volume":"27","author":"Emens","year":"2021","journal-title":"Cancer J"},{"key":"2025091917041560500_bnaf014-B18","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18888.1","article-title":"Triple-negative breast cancer: recent treatment advances","volume":"8","author":"Bergin","year":"2019","journal-title":"F1000Res"},{"issue":"9","key":"2025091917041560500_bnaf014-B19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2025091917041560500_bnaf014-B20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2025091917041560500_bnaf014-B21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"2025091917041560500_bnaf014-B22","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for breast cancer: what are we missing?","volume":"23","author":"Vonderheide","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025091917041560500_bnaf014-B23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"16","key":"2025091917041560500_bnaf014-B24","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.3390\/cancers13164233","article-title":"Tumor microenvironment in breast cancer-updates on therapeutic implications and pathologic assessment","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025091917041560500_bnaf014-B25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1479-5876-11-145","article-title":"Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients","volume":"11","author":"Ascierto","year":"2013","journal-title":"J Transl Med"},{"key":"2025091917041560500_bnaf014-B26","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"2025091917041560500_bnaf014-B27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"issue":"10","key":"2025091917041560500_bnaf014-B28","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.20101748","article-title":"Re-educating natural killer cells","volume":"207","author":"Sun","year":"2010","journal-title":"J Exp Med"},{"issue":"1","key":"2025091917041560500_bnaf014-B29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ni0102-6","article-title":"What is a natural killer cell?","volume":"3","author":"Moretta","year":"2002","journal-title":"Nat Immunol"},{"issue":"5","key":"2025091917041560500_bnaf014-B30","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y","article-title":"Human natural killer cells: their origin, receptors and function","volume":"32","author":"Moretta","year":"2002","journal-title":"Eur J Immunol"},{"issue":"12","key":"2025091917041560500_bnaf014-B31","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.4049\/jimmunol.146.12.4421","article-title":"Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM\/CD56)","volume":"146","author":"Lanier","year":"1991","journal-title":"J Immunol"},{"issue":"11","key":"2025091917041560500_bnaf014-B32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"issue":"3","key":"2025091917041560500_bnaf014-B33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.167.3.1141","article-title":"Cutting edge: the mouse NK cell-associated antigen recognized by DX5 moncoclonal antibody is CD49b (\u03b12 integrin, very late antigen-2)","volume":"167","author":"Arase","year":"2001","journal-title":"J Immunol"},{"issue":"12","key":"2025091917041560500_bnaf014-B34","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.4049\/jimmunol.176.12.7511","article-title":"Molecular and genetic basis for strain-dependent NK1. 1 alloreactivity of mouse NK cells","volume":"176","author":"Carlyle","year":"2006","journal-title":"J Immunol"},{"issue":"45","key":"2025091917041560500_bnaf014-B35","doi-asserted-by":"crossref","first-page":"18324","DOI":"10.1073\/pnas.1112064108","article-title":"Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor","volume":"108","author":"Narni-Mancinelli","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2025091917041560500_bnaf014-B36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri2154","article-title":"Developmental pathways that generate natural-killer-cell diversity in mice and humans","volume":"7","author":"Huntington","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2025091917041560500_bnaf014-B37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.immuni.2005.01.013","article-title":"A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells","volume":"22","author":"Freud","year":"2005","journal-title":"Immunity"},{"issue":"2","key":"2025091917041560500_bnaf014-B38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/icb.2009.94","article-title":"A potential role for RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny","volume":"88","author":"Andrews","year":"2010","journal-title":"Immunol Cell Biol"},{"issue":"5","key":"2025091917041560500_bnaf014-B39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0092-8674(00)80453-5","article-title":"Identification of clonogenic common lymphoid progenitors in mouse bone marrow","volume":"91","author":"Kondo","year":"1997","journal-title":"Cell"},{"issue":"20","key":"2025091917041560500_bnaf014-B40","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1182\/blood-2011-04-348912","article-title":"Identification of the earliest natural killer cell\u2013committed progenitor in murine bone marrow","volume":"118","author":"Fathman","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2025091917041560500_bnaf014-B41","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41590-021-01059-0","article-title":"Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states","volume":"22","author":"Triana","year":"2021","journal-title":"Nat Immunol"},{"issue":"13","key":"2025091917041560500_bnaf014-B42","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2010-04-281394","article-title":"Natural killer-cell differentiation by myeloid progenitors","volume":"117","author":"Grzywacz","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2025091917041560500_bnaf014-B43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.immunol.24.021605.090700","article-title":"Natural killer cell developmental pathways: a question of balance","volume":"24","author":"Di Santo","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.immunol.22.012703.104711","article-title":"The dynamic life of natural killer cells","volume":"22","author":"Yokoyama","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"2025091917041560500_bnaf014-B45","first-page":"45","volume-title":"Advances in Immunology. Vol 109","author":"Hesslein","year":"2011"},{"issue":"11","key":"2025091917041560500_bnaf014-B46","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1084\/jem.188.11.2067","article-title":"Stat5b is essential for natural killer cell\u2013mediated proliferation and cytolytic activity","volume":"188","author":"Imada","year":"1998","journal-title":"J Exp Med"},{"issue":"2","key":"2025091917041560500_bnaf014-B47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1074-7613(00)80025-4","article-title":"Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells","volume":"10","author":"Moriggl","year":"1999","journal-title":"Immunity"},{"issue":"2","key":"2025091917041560500_bnaf014-B48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coi.2005.01.005","article-title":"Distinguishing features of developing natural killer cells","volume":"17","author":"Vosshenrich","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"2025091917041560500_bnaf014-B49","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fimmu.2020.01945","article-title":"Molecular regulation of NK cell maturation","volume":"11","author":"Bi","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: from biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025091917041560500_bnaf014-B51","doi-asserted-by":"crossref","first-page":"647358","DOI":"10.3389\/fimmu.2021.647358","article-title":"Natural killer cell integrins and their functions in tissue residency","volume":"12","author":"Shannon","year":"2021","journal-title":"Front Immunol"},{"key":"2025091917041560500_bnaf014-B52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/B978-0-12-370454-2.00015-6","volume-title":"Natural Killer Cells","author":"Gismondi","year":"2010"},{"issue":"18","key":"2025091917041560500_bnaf014-B53","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1182\/blood-2011-06-362574","article-title":"Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking","volume":"118","author":"Mayol","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2025091917041560500_bnaf014-B54","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat Immunol"},{"issue":"11","key":"2025091917041560500_bnaf014-B55","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.4049\/jimmunol.1300090","article-title":"CX3CR1 regulates the maintenance of KLRG1+ NK cells into the bone marrow by promoting their entry into circulation","volume":"191","author":"Ponzetta","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/imm.13204","article-title":"Tbet promotes CXCR6 expression in immature natural killer cells and natural killer cell egress from the bone marrow","volume":"161","author":"Cuff","year":"2020","journal-title":"Immunology"},{"issue":"2","key":"2025091917041560500_bnaf014-B57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1172\/JCI16861","article-title":"Regulation of pulmonary fibrosis by chemokine receptor CXCR3","volume":"114","author":"Jiang","year":"2004","journal-title":"J Clin Invest"},{"issue":"1","key":"2025091917041560500_bnaf014-B58","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1038\/s41598-018-23099-7","article-title":"Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer","volume":"8","author":"Araujo","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"2025091917041560500_bnaf014-B59","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jcyt.2016.08.006","article-title":"Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor","volume":"18","author":"Yoon","year":"2016","journal-title":"Cytotherapy"},{"issue":"2","key":"2025091917041560500_bnaf014-B60","doi-asserted-by":"crossref","first-page":"e0225820","DOI":"10.1371\/journal.pone.0225820","article-title":"MicroRNA-155 governs SHIP-1 expression and localization in NK cells and regulates subsequent infiltration into murine AT3 mammary carcinoma","volume":"15","author":"Kandell","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"2025091917041560500_bnaf014-B61","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4149\/neo_2022_220615N635","article-title":"Differences in tolerogenic status of NK cells between luminal A type, luminal B type, and triple-negative breast cancer","volume":"69","author":"Star\u010devi\u0107","year":"2022","journal-title":"Neoplasma"},{"issue":"6","key":"2025091917041560500_bnaf014-B62","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.clbc.2021.02.003","article-title":"Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues","volume":"21","author":"Bouzidi","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"2025091917041560500_bnaf014-B63","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3389\/fimmu.2019.01703","article-title":"Does natural killer cell deficiency (NKD) increase the risk of cancer? NKD may increase the risk of some virus induced cancer","volume":"10","author":"Moon","year":"2019","journal-title":"Front Immunol"},{"issue":"9244","key":"2025091917041560500_bnaf014-B64","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"issue":"5757","key":"2025091917041560500_bnaf014-B65","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/284622a0","article-title":"Role of NK cells in tumour growth and metastasis in beige mice","volume":"284","author":"Talmadge","year":"1980","journal-title":"Nature"},{"issue":"6","key":"2025091917041560500_bnaf014-B66","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.4049\/jimmunol.1102461","article-title":"Recognition and prevention of tumor metastasis by the NK receptor NKp46\/NCR1","volume":"188","author":"Glasner","year":"2012","journal-title":"J Immunol"},{"issue":"4","key":"2025091917041560500_bnaf014-B67","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nri1055","article-title":"Immune functions encoded by the natural killer gene complex","volume":"3","author":"Yokoyama","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2025091917041560500_bnaf014-B68","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nri1863","article-title":"Self-tolerance of natural killer cells","volume":"6","author":"Raulet","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2025091917041560500_bnaf014-B69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri1570","article-title":"MHC class I molecules and KIRs in human history, health and survival","volume":"5","author":"Parham","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2025091917041560500_bnaf014-B70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol Today"},{"issue":"6055","key":"2025091917041560500_bnaf014-B71","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"K\u00e4rre","year":"1986","journal-title":"Nature"},{"issue":"9","key":"2025091917041560500_bnaf014-B72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0167-5699(00)01673-X","article-title":"Human NK-cell receptors","volume":"21","author":"Moretta","year":"2000","journal-title":"Immunol Today"},{"issue":"1","key":"2025091917041560500_bnaf014-B73","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1146\/annurev.immunol.17.1.875","article-title":"Regulation of immune responses through inhibitory receptors","volume":"17","author":"Long","year":"1999","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2025091917041560500_bnaf014-B74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/smim.2000.0214","article-title":"A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells","volume":"12","author":"Colonna","year":"2000","journal-title":"Semin Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B75","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev.iy.11.040193.003145","article-title":"The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex","volume":"11","author":"Yokoyama","year":"1993","journal-title":"Annu Rev Immunol"},{"issue":"7054","key":"2025091917041560500_bnaf014-B76","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"issue":"1","key":"2025091917041560500_bnaf014-B77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/cdd.2013.26","article-title":"Molecular mechanisms of natural killer cell activation in response to cellular stress","volume":"21","author":"Chan","year":"2014","journal-title":"Cell Death Differ"},{"issue":"21","key":"2025091917041560500_bnaf014-B78","first-page":"6178","article-title":"Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity","volume":"62","author":"Pende","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"2025091917041560500_bnaf014-B79","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"22","key":"2025091917041560500_bnaf014-B80","doi-asserted-by":"crossref","first-page":"12445","DOI":"10.1073\/pnas.93.22.12445","article-title":"Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium","volume":"93","author":"Groh","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025091917041560500_bnaf014-B81","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.0105-2896.2005.00287.x","article-title":"Innate and adaptive immunity in female genital tract: cellular responses and interactions","volume":"206","author":"Wira","year":"2005","journal-title":"Immunol Rev"},{"issue":"4","key":"2025091917041560500_bnaf014-B82","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000327014","article-title":"Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance","volume":"3","author":"Groth","year":"2011","journal-title":"J Innate Immun"},{"issue":"5","key":"2025091917041560500_bnaf014-B83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","article-title":"NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives","volume":"7","author":"Nigro C","year":"2019","journal-title":"Ann Transl Med"},{"issue":"1","key":"2025091917041560500_bnaf014-B84","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","article-title":"Activation, coactivation, and costimulation of resting human natural killer cells","volume":"214","author":"Bryceson","year":"2006","journal-title":"Immunol Rev"},{"issue":"1","key":"2025091917041560500_bnaf014-B85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","article-title":"Natural killer cell cytotoxicity: how do they pull the trigger?","volume":"128","author":"Topham","year":"2009","journal-title":"Immunology"},{"issue":"1","key":"2025091917041560500_bnaf014-B86","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.immunol.26.021607.090404","article-title":"Death by a thousand cuts: granzyme pathways of programmed cell death","volume":"26","author":"Chowdhury","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2025091917041560500_bnaf014-B87","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/nri1983","article-title":"Perforin-mediated target-cell death and immune homeostasis","volume":"6","author":"Voskoboinik","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2025091917041560500_bnaf014-B88","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1084\/jem.184.5.1781","article-title":"Decreased tumor surveillance in perforin-deficient mice","volume":"184","author":"van den Broek","year":"1996","journal-title":"J Exp Med"},{"issue":"5","key":"2025091917041560500_bnaf014-B89","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1128\/JVI.72.5.4515-4519.1998","article-title":"Theiler\u2019s virus infection of perforin-deficient mice","volume":"72","author":"Rossi","year":"1998","journal-title":"J Virol"},{"issue":"5","key":"2025091917041560500_bnaf014-B90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0952-7915(98)80227-6","article-title":"How do cytotoxic lymphocytes kill their targets?","volume":"10","author":"Shresta","year":"1998","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"2025091917041560500_bnaf014-B91","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nri1088","article-title":"What does it take to make a natural killer?","volume":"3","author":"Colucci","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2025091917041560500_bnaf014-B92","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1096\/fj.08-111005","article-title":"Life and death by death receptors","volume":"23","author":"Guicciardi","year":"2009","journal-title":"Faseb J"},{"issue":"9","key":"2025091917041560500_bnaf014-B93","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor\u2013mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"2025091917041560500_bnaf014-B94","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front Immunol"},{"key":"2025091917041560500_bnaf014-B95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","article-title":"The role of cytokines in the regulation of NK cells in the tumor environment","volume":"117","author":"Konjevi\u0107","year":"2019","journal-title":"Cytokine"},{"issue":"2","key":"2025091917041560500_bnaf014-B96","first-page":"1400","article-title":"NK cell-produced IFN-\u03b3 regulates cell growth and apoptosis of colorectal cancer by regulating IL-15","volume":"19","author":"Cui","year":"2020","journal-title":"Exp Ther Med"},{"issue":"12","key":"2025091917041560500_bnaf014-B97","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming","volume":"5","author":"Mart\u00edn-Fontecha","year":"2004","journal-title":"Nat Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B98","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/0008-5472.CAN-05-2429","article-title":"Natural killer cells produce T cell\u2013recruiting chemokines in response to antibody-coated tumor cells","volume":"66","author":"Roda","year":"2006","journal-title":"Cancer Res"},{"issue":"9","key":"2025091917041560500_bnaf014-B99","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"2025091917041560500_bnaf014-B100","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jcyt.2024.06.001","article-title":"IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy","volume":"26","author":"Biggi","year":"2024","journal-title":"Cytotherapy"},{"key":"2025091917041560500_bnaf014-B101","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3389\/fimmu.2020.01242","article-title":"Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"2025091917041560500_bnaf014-B102","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.7314\/APJCP.2014.15.8.3757","article-title":"Is the tumor infiltrating natural killer cell (NK-TILs) count in infiltrating ductal carcinoma of breast prognostically significant?","volume":"15","author":"Rathore","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"2025091917041560500_bnaf014-B103","doi-asserted-by":"crossref","first-page":"13673","DOI":"10.1038\/s41598-022-17857-x","article-title":"Pivotal models and biomarkers related to the prognosis of breast cancer based on the immune cell interaction network","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"2025091917041560500_bnaf014-B104","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12967-015-0535-8","article-title":"Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery","volume":"13","author":"Verma","year":"2015","journal-title":"J Transl Med"},{"issue":"3","key":"2025091917041560500_bnaf014-B105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14737159.2018.1439382","article-title":"The breast tumor microenvironment: role in cancer development, progression and response to therapy","volume":"18","author":"Mittal","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"2025091917041560500_bnaf014-B106","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2025091917041560500_bnaf014-B107","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1158\/1078-0432.CCR-18-2365","article-title":"NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival","volume":"25","author":"Muntasell","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"686","key":"2025091917041560500_bnaf014-B108","doi-asserted-by":"crossref","first-page":"eabl4414","DOI":"10.1126\/scitranslmed.abl4414","article-title":"Immature natural killer cells promote progression of triple-negative breast cancer","volume":"15","author":"Thacker","year":"2023","journal-title":"Sci Transl Med"},{"issue":"4","key":"2025091917041560500_bnaf014-B109","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/19420862.2017.1305530","article-title":"Drifts in ADCC-related quality attributes of Herceptin\u00ae: impact on development of a trastuzumab biosimilar","volume":"9","author":"Kim","year":"2017","journal-title":"MAbs"},{"key":"2025091917041560500_bnaf014-B110","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3389\/fimmu.2017.01426","article-title":"Herceptin enhances the antitumor effect of natural killer cells on breast cancer cells expressing human epidermal growth factor receptor-2","volume":"8","author":"Tian","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"2025091917041560500_bnaf014-B111","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation","volume":"108","author":"De Maria","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2025091917041560500_bnaf014-B112","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"2025091917041560500_bnaf014-B113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1479-5876-6-25","article-title":"Correlation between NK function and response to trastuzumab in metastatic breast cancer patients","volume":"6","author":"Beano","year":"2008","journal-title":"J Transl Med"},{"issue":"2","key":"2025091917041560500_bnaf014-B114","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","article-title":"Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?","volume":"94","author":"Arnould","year":"2006","journal-title":"Br J Cancer"},{"issue":"4","key":"2025091917041560500_bnaf014-B115","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"2025091917041560500_bnaf014-B116","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025091917041560500_bnaf014-B117","first-page":"211","article-title":"Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells","volume":"3","author":"Diessner","year":"2013","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2025091917041560500_bnaf014-B118","doi-asserted-by":"crossref","first-page":"255","DOI":"10.18632\/oncotarget.6353","article-title":"Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition","volume":"7","author":"Di Modica","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2025091917041560500_bnaf014-B119","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1400271","article-title":"Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1","volume":"193","author":"Soriani","year":"2014","journal-title":"J Immunol"},{"issue":"4","key":"2025091917041560500_bnaf014-B120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3390\/cancers13040711","article-title":"Natural killer cells and anti-cancer therapies: reciprocal effects on immune function and therapeutic response","volume":"13","author":"Toffoli","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025091917041560500_bnaf014-B121","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.2910550506","article-title":"Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer","volume":"55","author":"Sewell","year":"1993","journal-title":"Int J Cancer"},{"issue":"4","key":"2025091917041560500_bnaf014-B122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0960-7404(94)90036-1","article-title":"Natural immunity in breast cancer patients during neoadjuvant chemotherapy and after surgery","volume":"3","author":"Beitsch","year":"1994","journal-title":"Surg Oncol"},{"issue":"1","key":"2025091917041560500_bnaf014-B123","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.bjc.6603840","article-title":"NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy","volume":"97","author":"Mozaffari","year":"2007","journal-title":"Br J Cancer"},{"issue":"2","key":"2025091917041560500_bnaf014-B124","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09553002.2016.1115136","article-title":"Post-irradiation viability and cytotoxicity of natural killer cells isolated from human peripheral blood using different methods","volume":"92","author":"Hietanen","year":"2016","journal-title":"Int J Radiat Biol"},{"issue":"10","key":"2025091917041560500_bnaf014-B125","first-page":"428","article-title":"Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy","volume":"29","author":"Yang","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"2025091917041560500_bnaf014-B126","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.critrevonc.2019.02.014","article-title":"Radiation therapy for young women with early breast cancer: current state of the art","volume":"137","author":"Meattini","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2025091917041560500_bnaf014-B127","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/2326-6066.CIR-22-0391","article-title":"Increased CaMKK2 expression is an adaptive response that maintains the fitness of tumor-infiltrating natural killer cells","volume":"11","author":"Juras","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2025091917041560500_bnaf014-B128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrd4506","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens","volume":"14","author":"Childs","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2025091917041560500_bnaf014-B129","doi-asserted-by":"crossref","first-page":"1356666","DOI":"10.3389\/fimmu.2024.1356666","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity","volume":"15","author":"Stenger","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"2025091917041560500_bnaf014-B130","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"issue":"7","key":"2025091917041560500_bnaf014-B131","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12943-023-01737-7","article-title":"NK cells are never alone: crosstalk and communication in tumour microenvironments","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol Cancer"},{"issue":"8","key":"2025091917041560500_bnaf014-B133","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","article-title":"Natural killer cells at the frontline in the fight against cancer","volume":"15","author":"Co\u00ebnon","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"2025091917041560500_bnaf014-B134","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2025091917041560500_bnaf014-B135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.soncn.2015.02.002","article-title":"Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach","volume":"31","author":"Reinbolt","year":"2015","journal-title":"Semin Oncol Nurs"},{"issue":"2","key":"2025091917041560500_bnaf014-B136","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","article-title":"A comprehensive immunologic portrait of triple-negative breast cancer","volume":"11","author":"Liu","year":"2018","journal-title":"Transl Oncol"},{"key":"2025091917041560500_bnaf014-B137","first-page":"PO.19.00350","article-title":"Immunological differences between immune-rich estrogen receptor-positive and immune-rich triple-negative breast cancers","volume":"4","author":"O'Meara","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"2025091917041560500_bnaf014-B138","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/endrev\/bnac017","article-title":"Estrogen receptor signaling in the immune system","volume":"44","author":"Chakraborty","year":"2023","journal-title":"Endocr Rev"},{"key":"2025091917041560500_bnaf014-B139","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"1","key":"2025091917041560500_bnaf014-B140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/cimm.2002.1886","article-title":"Natural killer cells express estrogen receptor-alpha and estrogen receptor-beta and can respond to estrogen via a non-estrogen receptor-alpha-mediated pathway","volume":"214","author":"Curran","year":"2001","journal-title":"Cell Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B141","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/nyas.13523","article-title":"Mouse models to evaluate the role of estrogen receptor \u03b1 in skeletal maintenance and adaptation","volume":"1410","author":"Rooney","year":"2017","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2025091917041560500_bnaf014-B142","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00198-009-0963-5","article-title":"Sex hormones and their receptors in bone homeostasis: insights from genetically modified mouse models","volume":"21","author":"Vico","year":"2010","journal-title":"Osteoporos Int"},{"issue":"13","key":"2025091917041560500_bnaf014-B143","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.intimp.2007.09.017","article-title":"Modulation of 17\u03b2-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors","volume":"7","author":"Hao","year":"2007","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2025091917041560500_bnaf014-B144","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/cmi.2008.44","article-title":"17beta-estradiol suppresses cytotoxicity and proliferative capacity of murine splenic NK1.1+ cells","volume":"5","author":"Hao","year":"2008","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1210\/er.2003-0021","article-title":"Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives","volume":"26","author":"Dosiou","year":"2005","journal-title":"Endocr Rev"},{"issue":"3","key":"2025091917041560500_bnaf014-B146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000293766","article-title":"NK cell activity and estrogen hormone levels during normal human pregnancy","volume":"25","author":"Gabrilovac","year":"1988","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"2025091917041560500_bnaf014-B147","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jri.2005.07.006","article-title":"Effect of estrogen\/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women","volume":"69","author":"Stopi\u0144ska-G\u0142uszak","year":"2006","journal-title":"J Reprod Immunol"},{"issue":"3","key":"2025091917041560500_bnaf014-B148","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-5122(96)01063-8","article-title":"Effect of estrogen replacement therapy on natural killer cell activity in postmenopausal women","volume":"25","author":"Albrecht","year":"1996","journal-title":"Maturitas"},{"issue":"12","key":"2025091917041560500_bnaf014-B149","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1054\/bjoc.2000.1490","article-title":"Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity","volume":"83","author":"Shakhar","year":"2000","journal-title":"Br J Cancer"},{"issue":"2","key":"2025091917041560500_bnaf014-B150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/gyno.2001.6153","article-title":"The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells","volume":"81","author":"Yovel","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"11","key":"2025091917041560500_bnaf014-B151","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/art.1780221110","article-title":"Effect of estrogen on natural killer cells","volume":"22","author":"Seaman","year":"1979","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2025091917041560500_bnaf014-B152","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.4049\/jimmunol.121.6.2193","article-title":"beta-estradiol reduces natural killer cells in mice","volume":"121","author":"Seaman","year":"1978","journal-title":"J Immunol"},{"issue":"6","key":"2025091917041560500_bnaf014-B153","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.4049\/jimmunol.122.6.2541","article-title":"Natural killer cells, bone, and the bone marrow: studies in estrogen-treated mice and in congenitally osteopetrotic (mi\/mi) mice","volume":"122","author":"Seaman","year":"1979","journal-title":"J Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B154","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/cimm.1994.1262","article-title":"Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation","volume":"158","author":"Nilsson","year":"1994","journal-title":"Cell Immunol"},{"issue":"2","key":"2025091917041560500_bnaf014-B155","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/1097-0142(19950115)75:2<591::AID-CNCR2820750224>3.0.CO;2-U","article-title":"Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol","volume":"75","author":"Baral","year":"1995","journal-title":"Cancer"},{"issue":"3","key":"2025091917041560500_bnaf014-B156","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01525437","article-title":"In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer","volume":"37","author":"Robinson","year":"1993","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2025091917041560500_bnaf014-B157","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0277-5379(87)90313-0","article-title":"Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer","volume":"23","author":"Berry","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"1","key":"2025091917041560500_bnaf014-B158","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01805743","article-title":"Influence of adjuvant tamoxifen on blood lymphocytes","volume":"12","author":"Rotstein","year":"1988","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2025091917041560500_bnaf014-B159","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/humrep\/dev067","article-title":"Estrogen-dependent regulation of human uterine natural killer cells promotes vascular remodelling via secretion of CCL2","volume":"30","author":"Gibson","year":"2015","journal-title":"Hum Reprod"},{"issue":"3","key":"2025091917041560500_bnaf014-B160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1940-6207.CAPR-13-0345","article-title":"Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells","volume":"7","author":"Janakiram","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"2025091917041560500_bnaf014-B161","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02778145","article-title":"Differential effects of estrogen and medroxyprogesterone on basal and stress-induced growth hormone release, IGF-1 levels, and cellular immunity in postmenopausal women","volume":"7","author":"Malarkey","year":"1997","journal-title":"Endocrine"},{"issue":"2","key":"2025091917041560500_bnaf014-B162","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0015-0282(00)00622-1","article-title":"Hormone replacement therapy reverses the decrease in natural killer cytotoxicity but does not reverse the decreases in the T-cell subpopulation or interferon-gamma production in postmenopausal women","volume":"74","author":"Yang","year":"2000","journal-title":"Fertil Steril"},{"key":"2025091917041560500_bnaf014-B163","doi-asserted-by":"crossref","first-page":"918550","DOI":"10.3389\/fimmu.2022.918550","article-title":"Uterine natural killer cells: a rising star in human pregnancy regulation","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B164","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0165-2478(93)90065-A","article-title":"Enhancing effect of 17\u03b2-estradiol on human NK cell activity","volume":"36","author":"Sorachi","year":"1993","journal-title":"Immunol Lett"},{"issue":"3","key":"2025091917041560500_bnaf014-B165","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/en.2005-0996","article-title":"Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells","volume":"147","author":"Jiang","year":"2006","journal-title":"Endocrinology"},{"issue":"28","key":"2025091917041560500_bnaf014-B166","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1038\/sj.onc.1210197","article-title":"Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells","volume":"26","author":"Jiang","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"2025091917041560500_bnaf014-B167","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ijc.2910470323","article-title":"Enhancement of natural-killer-cell susceptibility of human breast-cancer cells by estradiol and v-Ha-ras oncogene","volume":"47","author":"Screpanti","year":"1991","journal-title":"Int J Cancer"},{"issue":"6","key":"2025091917041560500_bnaf014-B168","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1042\/EBC20200174","article-title":"Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer","volume":"65","author":"Haines","year":"2021","journal-title":"Essays Biochem"},{"issue":"11","key":"2025091917041560500_bnaf014-B169","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.4049\/jimmunol.173.11.6760","article-title":"Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone","volume":"173","author":"Sentman","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"2025091917041560500_bnaf014-B170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clim.2008.07.005","article-title":"Estradiol regulates MICA expression in human endometrial cells","volume":"129","author":"Basu","year":"2008","journal-title":"Clin Immunol"},{"key":"2025091917041560500_bnaf014-B171","first-page":"17","article-title":"Upregulation of MICA on high-grade invasive operable breast carcinoma","volume":"7","author":"Madjd","year":"2007","journal-title":"Cancer Immun"},{"issue":"56","key":"2025091917041560500_bnaf014-B172","doi-asserted-by":"crossref","first-page":"96384","DOI":"10.18632\/oncotarget.21466","article-title":"Prognostic value of MICA\/B in cancers: a systematic review and meta-analysis","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"3a","key":"2025091917041560500_bnaf014-B173","first-page":"1849","article-title":"Antiestrogens affect both pathways of killer cell-mediated oncolysis","volume":"20","author":"Haeryfar","year":"2000","journal-title":"Anticancer Res"},{"issue":"6","key":"2025091917041560500_bnaf014-B174","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.coph.2010.09.007","article-title":"The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer","volume":"10","author":"McDonnell","year":"2010","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"2025091917041560500_bnaf014-B175","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1038\/s41598-025-89915-z","article-title":"Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis","volume":"15","author":"Alwashmi","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"2025091917041560500_bnaf014-B176","doi-asserted-by":"crossref","first-page":"e12705","DOI":"10.1111\/sji.12705","article-title":"The yin-yang of the interaction between myelomonocytic cells and NK cells","volume":"88","author":"Molgora","year":"2018","journal-title":"Scand J Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B177","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12879-018-2991-2","article-title":"IL-10(+) NK and TGF-\u03b2(+) NK cells play negative regulatory roles in HIV infection","volume":"18","author":"Jiang","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"12","key":"2025091917041560500_bnaf014-B178","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.4049\/jimmunol.1701461","article-title":"Canonical TGF-\u03b2 signaling pathway represses human NK cell metabolism","volume":"200","author":"Zaiatz-Bittencourt","year":"2018","journal-title":"J Immunol"},{"issue":"415","key":"2025091917041560500_bnaf014-B179","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"issue":"4","key":"2025091917041560500_bnaf014-B180","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"2025091917041560500_bnaf014-B181","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.0730640100","article-title":"Transforming growth factor \u03b21 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells","volume":"100","author":"Castriconi","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2025091917041560500_bnaf014-B182","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.4049\/jimmunol.181.6.3784","article-title":"TGF-\u03b2 utilizes SMAD3 to inhibit CD16-mediated IFN-\u03b3 production and antibody-dependent cellular cytotoxicity in human NK cells","volume":"181","author":"Trotta","year":"2008","journal-title":"J Immunol"},{"issue":"9","key":"2025091917041560500_bnaf014-B183","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1093\/brain\/awl205","article-title":"TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells","volume":"129","author":"Eisele","year":"2006","journal-title":"Brain"},{"issue":"2","key":"2025091917041560500_bnaf014-B184","doi-asserted-by":"crossref","first-page":"e002044","DOI":"10.1136\/jitc-2020-002044","article-title":"TGF\u03b2 drives NK cell metabolic dysfunction in human metastatic breast cancer","volume":"9","author":"Slattery","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2025091917041560500_bnaf014-B185","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1172\/JCI116871","article-title":"Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell\/host TGF-beta interactions in human breast cancer progression","volume":"92","author":"Arteaga","year":"1993","journal-title":"J Clin Invest"},{"issue":"5","key":"2025091917041560500_bnaf014-B186","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/cmi.2015.42","article-title":"The breast tumor microenvironment alters the phenotype and function of natural killer cells","volume":"13","author":"Krneta","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"2025091917041560500_bnaf014-B187","first-page":"1553","article-title":"Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-\u03b2 signaling pathway","volume":"8","author":"Zhao","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2025091917041560500_bnaf014-B188","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41467-017-02696-6","article-title":"Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy","volume":"9","author":"Ravi","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"2025091917041560500_bnaf014-B189","doi-asserted-by":"crossref","first-page":"e1426519","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGF\u03b2 trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025091917041560500_bnaf014-B190","doi-asserted-by":"crossref","first-page":"910595","DOI":"10.3389\/fimmu.2022.910595","article-title":"Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies","volume":"13","author":"Seliger","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"2025091917041560500_bnaf014-B191","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"2025091917041560500_bnaf014-B192","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","article-title":"Metastatic latency and immune evasion through autocrine inhibition of WNT","volume":"165","author":"Malladi","year":"2016","journal-title":"Cell"},{"issue":"12","key":"2025091917041560500_bnaf014-B193","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.4049\/jimmunol.171.12.6891","article-title":"Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma","volume":"171","author":"Doubrovina","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"2025091917041560500_bnaf014-B194","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1172\/JCI200422206","article-title":"Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer","volume":"114","author":"Wu","year":"2004","journal-title":"J Clin Invest"},{"issue":"6383","key":"2025091917041560500_bnaf014-B195","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.aao0505","article-title":"Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity","volume":"359","author":"Ferrari de Andrade","year":"2018","journal-title":"Science"},{"issue":"12","key":"2025091917041560500_bnaf014-B196","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","article-title":"Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB","volume":"96","author":"Groh","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025091917041560500_bnaf014-B197","doi-asserted-by":"crossref","first-page":"e000233","DOI":"10.1136\/jitc-2019-000233","article-title":"Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein","volume":"8","author":"Torres","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025091917041560500_bnaf014-B198","doi-asserted-by":"crossref","first-page":"713158","DOI":"10.3389\/fimmu.2021.713158","article-title":"Leveraging NKG2D ligands in immuno-oncology","volume":"12","author":"Fuertes","year":"2021","journal-title":"Front Immunol"},{"key":"2025091917041560500_bnaf014-B199","doi-asserted-by":"crossref","first-page":"652266","DOI":"10.3389\/fonc.2021.652266","article-title":"Hypoxia in breast cancer-scientific translation to therapeutic and diagnostic clinical applications","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"2025091917041560500_bnaf014-B200","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front Immunol"},{"key":"2025091917041560500_bnaf014-B201","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3389\/fimmu.2018.02358","article-title":"Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration","volume":"9","author":"Parodi","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B202","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"2025091917041560500_bnaf014-B203","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-Associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"2025091917041560500_bnaf014-B204","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/2326-6066.CIR-18-0481","article-title":"Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis","volume":"7","author":"Harmon","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2025091917041560500_bnaf014-B205","doi-asserted-by":"crossref","first-page":"107855","DOI":"10.1016\/j.celrep.2020.107855","article-title":"Inflammation-induced lactate leads to rapid loss of hepatic tissue-resident NK cells","volume":"32","author":"Dodard","year":"2020","journal-title":"Cell Rep"},{"issue":"2","key":"2025091917041560500_bnaf014-B206","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/0008-5472.CAN-10-2581","article-title":"Cam kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells","volume":"71","author":"Frigo","year":"2011","journal-title":"Cancer Res"},{"issue":"9","key":"2025091917041560500_bnaf014-B207","doi-asserted-by":"crossref","first-page":"110447","DOI":"10.1016\/j.celrep.2022.110447","article-title":"Tumor-educated T(regs) drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche","volume":"38","author":"Kos","year":"2022","journal-title":"Cell Rep"},{"issue":"1","key":"2025091917041560500_bnaf014-B208","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1038\/s41467-020-18125-0","article-title":"Dual roles of neutrophils in metastatic colonization are governed by the host NK cell status","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"issue":"23","key":"2025091917041560500_bnaf014-B209","doi-asserted-by":"crossref","first-page":"e2221707120","DOI":"10.1073\/pnas.2221707120","article-title":"Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion","volume":"120","author":"Han","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"2025091917041560500_bnaf014-B210","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025091917041560500_bnaf014-B211","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/imcb.12658","article-title":"Advances in natural killer cell therapies for breast cancer","volume":"101","author":"Kiaei","year":"2023","journal-title":"Immunol Cell Biol"},{"issue":"12","key":"2025091917041560500_bnaf014-B212","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2025091917041560500_bnaf014-B213","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2025091917041560500_bnaf014-B214","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025091917041560500_bnaf014-B215","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2025091917041560500_bnaf014-B216","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line\u201430 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"2025091917041560500_bnaf014-B217","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"issue":"1","key":"2025091917041560500_bnaf014-B218","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural killer group 2D receptor and its ligands in cancer immune escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol Cancer"},{"key":"2025091917041560500_bnaf014-B219","doi-asserted-by":"crossref","first-page":"707542","DOI":"10.3389\/fimmu.2021.707542","article-title":"CAR-NK cells: from natural basis to design for kill","volume":"12","author":"Khawar","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B220","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark Res"},{"issue":"2","key":"2025091917041560500_bnaf014-B221","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol Ther"},{"issue":"1","key":"2025091917041560500_bnaf014-B222","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/or.2020.7862","article-title":"Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol Rep"},{"issue":"11","key":"2025091917041560500_bnaf014-B223","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"issue":"5","key":"2025091917041560500_bnaf014-B224","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"issue":"11","key":"2025091917041560500_bnaf014-B225","first-page":"3081","article-title":"Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer","volume":"60","author":"Tang","year":"2000","journal-title":"Cancer Res"},{"issue":"10","key":"2025091917041560500_bnaf014-B226","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1586\/era.10.76","article-title":"Personalized medicine for non-small-cell lung cancer","volume":"10","author":"Mok","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"2025091917041560500_bnaf014-B227","doi-asserted-by":"crossref","first-page":"188789","DOI":"10.1016\/j.bbcan.2022.188789","article-title":"Can EGFR be a therapeutic target in breast cancer?","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"25","key":"2025091917041560500_bnaf014-B228","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2006.09.6578","article-title":"A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer","volume":"25","author":"Smith","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025091917041560500_bnaf014-B229","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-011-1352-2","article-title":"Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial","volume":"126","author":"Bernsdorf","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2025091917041560500_bnaf014-B230","doi-asserted-by":"crossref","first-page":"181","DOI":"10.21873\/cgp.20030","article-title":"Prognostic evaluation of epidermal growth factor receptor (EGFR) genotype and phenotype parameters in triple-negative breast cancers","volume":"14","author":"Levva","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"issue":"2","key":"2025091917041560500_bnaf014-B231","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr2857","article-title":"Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy","volume":"13","author":"Teng","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"11","key":"2025091917041560500_bnaf014-B232","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdp202","article-title":"Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer","volume":"20","author":"Green","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"2025091917041560500_bnaf014-B233","doi-asserted-by":"crossref","first-page":"e12858","DOI":"10.1111\/cpr.12858","article-title":"Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor","volume":"53","author":"Liu","year":"2020","journal-title":"Cell Prolif"},{"issue":"19","key":"2025091917041560500_bnaf014-B234","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2025091917041560500_bnaf014-B235","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","article-title":"Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Sci Rep"},{"issue":"9","key":"2025091917041560500_bnaf014-B236","first-page":"4455","article-title":"Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells","volume":"11","author":"Lin","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2025091917041560500_bnaf014-B237","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/2326-6066.CIR-20-1023","article-title":"PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress","volume":"10","author":"Klopotowska","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025091917041560500_bnaf014-B238","doi-asserted-by":"crossref","first-page":"1207276","DOI":"10.3389\/fimmu.2023.1207276","article-title":"Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2025091917041560500_bnaf014-B239","doi-asserted-by":"crossref","first-page":"1039969","DOI":"10.3389\/fimmu.2022.1039969","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"Nikkhoi","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"2025091917041560500_bnaf014-B240","doi-asserted-by":"crossref","first-page":"1854529","DOI":"10.1080\/2162402X.2020.1854529","article-title":"Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response","volume":"10","author":"Raynaud","year":"2020","journal-title":"Oncoimmunology"},{"issue":"31","key":"2025091917041560500_bnaf014-B241","doi-asserted-by":"crossref","first-page":"32075","DOI":"10.18632\/oncotarget.5135","article-title":"HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity","volume":"6","author":"Peipp","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"2025091917041560500_bnaf014-B242","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.3390\/ijms241713156","article-title":"Targeting NKG2DL with bispecific NKG2D-CD16 and NKG2D-CD3 fusion proteins on triple-negative breast cancer","volume":"24","author":"Kaidun","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"27","key":"2025091917041560500_bnaf014-B243","doi-asserted-by":"crossref","first-page":"eaba8564","DOI":"10.1126\/sciadv.aba8564","article-title":"Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy","volume":"6","author":"Au","year":"2020","journal-title":"Sci Adv"},{"issue":"23","key":"2025091917041560500_bnaf014-B244","doi-asserted-by":"crossref","first-page":"8914","DOI":"10.3390\/ijms21238914","article-title":"Functional domain order of an anti-EGFR\u00d7anti-CD16 bispecific diabody involving NK cell activation","volume":"21","author":"Kuwahara","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2025091917041560500_bnaf014-B245","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.4110\/in.2020.20.e14","article-title":"NK Cell-based immunotherapies in cancer","volume":"20","author":"Shin","year":"2020","journal-title":"Immune Netw"},{"issue":"11","key":"2025091917041560500_bnaf014-B246","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.3390\/cancers12113189","article-title":"IL-2 and anti-TGF-\u03b2 promote NK cell reconstitution and anti-tumor effects after syngeneic hematopoietic stem cell transplantation","volume":"12","author":"Alvarez","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025091917041560500_bnaf014-B247","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.23239","article-title":"Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells","volume":"112","author":"Carrega","year":"2008","journal-title":"Cancer"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnaf014\/63138896\/bnaf014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/46\/5\/690\/63138896\/bnaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/46\/5\/690\/63138896\/bnaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:04:51Z","timestamp":1758315891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/46\/5\/690\/8128060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":247,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,9]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnaf014","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,9]]}}}